Price
$2.67
Decreased by -4.30%
Dollar Volume
65.65 K
ADR%
8.41
Earnings Report Date (estimate)
Mar 27, 23 (-1.4)
Market Cap.
12.12 M
Shares Float
2.92 M
Shares Outstanding
4.54 M
Beta
1.93
Price / Earnings
-8.75
BPR
553.81
20D Range
2.05 3.19
50D Range
1.79 3.30
200D Range
0.20 11.50
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 1, 22 -1.40
Increased by +0.00%
-1.65
Increased by +15.15%
Aug 15, 22 -1.80
Decreased by -50.00%
-1.80
May 5, 22 -1.80
Decreased by -12.50%
-1.60
Decreased by -12.50%
Mar 28, 22 -1.60
Increased by +33.33%
-1.60
Nov 12, 21 -1.40
Increased by +46.15%
-1.40
Aug 11, 21 -1.20
Increased by +57.14%
-1.40
Increased by +14.29%
May 11, 21 -1.60
Increased by +66.67%
-1.00
Decreased by -60.00%
Mar 24, 21 -2.40
Increased by +53.85%
-2.60
Increased by +7.69%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-6.37 M
Increased by +5.01%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-7.99 M
Decreased by -40.56%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-8.42 M
Decreased by -20.75%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-6.80 M
Decreased by -36.09%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-6.70 M
Decreased by -33.47%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-5.69 M
Decreased by -29.52%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-6.97 M
Decreased by -3.36%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-5.00 M
Increased by +30.95%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.